CompletedPhase 4NCT04807517
Buspirone Treatment of Anxiety in Williams Syndrome
Studying Williams syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Robyn P Thom, MDMassachusetts General Hospital
- Intervention
- Buspirone(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 5-65 years · All sexes
- Timeline
- 2021 – 2023
Study locations (1)
- Lurie Center for Autism, Lexington, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04807517 on ClinicalTrials.govOther trials for Williams syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06930417Characterization and Natural History of Williams Syndrome and Other Chromosome 7q11.23 VariantsUniversity of Pennsylvania
- RECRUITINGNANCT07285720Phonological Constraints on Language Development in Individuals With Williams SyndromeCentre Hospitalier Universitaire, Amiens
- ACTIVE NOT RECRUITINGPHASE2NCT06087757Clemastine Treatment in Individuals With Williams SyndromeSheba Medical Center